Home » Topics » BioWorld Science, Cancer

BioWorld Science, Cancer
RSS

University of South Australia discovers new candidate for glioblastoma

Feb. 5, 2021

New Aurora kinase inhibitors described by Wigen Biomedicine Technology

Feb. 5, 2021

FDA grants accelerated approval to Tepmetko for metastatic NSCLC with METex14 skipping alterations

Feb. 4, 2021

Erlotinib plus anlotinib shows promise in EGFR-mutated NSCLC

Feb. 4, 2021

ABTL-0812 plus paclitaxel and carboplatin result in increased efficacy in NSCLC

Feb. 4, 2021

RCC-33 reduces tumor volume in mice inoculated with colorectal cancer cells

Feb. 4, 2021

Phase Ib data show lack of objective response for CMP-001 plus atezolizumab in NSCLC

Feb. 4, 2021

Novartis discovers AKR1C3-dependent GTPase KRAS inhibitors

Feb. 4, 2021

Cybrexa 3 patents peptide conjugates of microtubule-targeting agents

Feb. 4, 2021

New cannabinoid CB1 and CB2 receptor ligands identified at Canopy Growth Corp.

Feb. 4, 2021

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 13, 2026.
FENS 2026: Next-gen biologics take on brain disease
BioWorld
Whether by fine-tuning neurotransmitter signaling or silencing disease-associated genes, emerging biologic therapies are reshaping neuroscience drug development,...
Ionis, AZ shares down on unexpected Wainua flop in cardiomyopathy
BioWorld
News of the unexpected phase III failure of the gene silencing drug Wainua (eplontersen) in the treatment of transthyretin-mediated amyloid cardiomyopathy sent...
Neurovalens granted FDA approval for PTSD therapy for US veterans
BioWorld
Veterans in the U.S. suffering from post-traumatic stress disorder (PTSD) now have access to Neurovalens Ltd.’s Modius Spero, a wearable neuromodulation device,...
NRF2 activators reported in Vailima Peninsula patent
BioWorld Science
Vailima Peninsula Pty Ltd. has discovered new nuclear factor erythroid 2-related factor 2 (NFE2L2; NRF2) activators potentially useful for the treatment of...